March 2016, Vol. 5, No. 2

← Back to Issue

Biomarker Panel Warrants More Study as Aid to Early CRC Detection

Gastrointestinal Cancers Symposium

A panel of 4 blood-derived biomarkers showed promise as an aid to early detection of colorectal cancer (CRC), as reported at the 2016 Gastrointestinal Cancers Symposium.

The panel yielded a negative predictive value (NPV) exceeding 90% for CRC, the combination of CRC and high-risk adenomas, and CRC plus other cancers. The biomarker assay demonstrated fair to good performance characteristics associated with area under the receiver operating characteristic curve (AUC) ranging between 0.70 and 0.80.

“We have demonstrated that a panel of blood-based markers can significantly predict the probabilities of the chosen end points,” said Ib J. Christensen, MSc, a biostatistician at Hvidovre Hospital and the University of Copenhagen in Denmark. “In the future, we hope to improve the results by including new markers and performing alternative analytic approaches, such as the adaptive index model.”

Christensen presented findings from a study designed to evaluate combinations of existing biomarkers to aid in the detection of colorectal neoplasia. After optimizing the biomarker combination, investigators evaluated biomarker-based approaches to early detection of CRC.

The investigation began with the identification of 8 biomarkers with evidence suggesting associations with CRC. The 8 markers were: carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein (hs-CRP), alpha-fetoprotein, ferritin, galectin-3, cytokeratin fragment 21-1 (CyFra21-1), cancer antigen 19-9, and tissue inhibitor of metalloproteinase-1.

To evaluate the markers, investigators recruited adult patients referred for a first-ever colonoscopy in follow-up to symptoms suggesting the presence of colorectal neoplasia. Patients with a history of CRC were excluded.

Subsequently, usable blood samples were obtained from almost 4700 patients. Colonoscopy identified colon cancer in 319 patients, rectal cancer in 193, colonic adenomas in 515, rectal adenomas in 174, other types of cancer in 177, and nonmalignant findings in 1342 (such as diverticula and ulcerative colitis). The remaining 1978 patients had what Christensen described as “clean colons.”

Assessment of the blood samples produced a separation among the biomarkers in terms of their ability to detect the chosen end points. Investigators found that a panel of 4 biomarkers (CEA, hs-CRP, ferritin, and CyFra21-1) performed as well as a panel comprising all 8 biomarkers.

The final model included the 4 protein markers plus patient age and sex. For the end point of CRC cancer plus high-risk adenomas, the model had an AUC of 0.71. For CRC only, the performance improved to 0.81.

The investigators calculated specificity, positive predictive value (PPV), and NPV for different levels of sensitivity. With 90% sensitivity for CRC plus high-risk adenomas, the model had a specificity of 33%, a PPV of 25%, and an NPV of 93%. For 90% sensitivity to detect only CRC, the model had a specificity of 48%, a PPV of 18%, and an NPV of 97%. For CRC and other cancers, the panel had a PPV of 20% and an NPV of 96%.

Letter to Our Readers - March 10, 2016

The Wide Range of Topics Under the Personalized Care Umbrella

Dear Colleague, One important lesson we have learned from our work in personalizing care for oncology patients is that there are many more considerations in implementing care aside from the obvious premises of targeted therapies, companion diagnostics, and next-generation sequencing. There is an ever-broadening array of considerations that goes into [ Read More ]

Genitourinary Cancers Symposium - March 10, 2016

Adjuvant Chemoradiotherapy May Provide Benefit in Locally Advanced Bladder Cancer

In the United States, the standard of care for locally advanced bladder cancer after radical cystectomy is to “consider” adjuvant chemotherapy and adjuvant radiation. In a 3-arm randomized trial, adjuvant radiation therapy alone or combined with chemotherapy (ie, chemoradiotherapy) did not significantly improve disease-free survival (DFS) compared with adjuvant chemotherapy [ Read More ]